Search results for Domagrozumab
Domagrozumab Biosimilar – Anti-MSTN , GDF8 mAb – Research Grade, ProteoGenix, PX-TA1426
Description of Domagrozumab Biosimilar - Anti-MSTN , GDF8 mAb - Research Grade General information on Anti-MSTN /GDF8[Homo sapiens] (Domagrozumab) Monoclonal Antibody Domagrozumab is investigated for the treatment of Duchenne muscular dystrophy (DMD).
Host
Reactivity
Applications
Conjugation
Domagrozumab, Abbexa, abx831383
Domagrozumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MSTN/GDF8, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Domagrozumab Biosimilar - Research Grade, ichor.bio, ICH5485
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Research Grade Domagrozumab (HT343036), abinScience, HT343036
Host
Humanized
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.